{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:18:39Z","timestamp":1780730319824,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["G00594"],"award-info":[{"award-number":["G00594"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enzyme replacement therapy (ERT) with olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is being developed to treat patients with ASM deficiency (ASMD), commonly known as Niemann\u2013Pick disease (NPD) types A or B. This study assessed the effect of ERT on lipid parameters and inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Serum and plasma samples from five adults with NPD type B (NPD-B) who received olipudase alfa ERT for 26\u00a0weeks were analysed. We also collected fasting blood samples from fifteen age- and sex-matched participants as reference and comparison group. We measured fasting lipid profile, apolipoproteins B48 and B100 (apoB48 and apoB100), apolipoprotein A1 (apoA1), proprotein convertase subtilisin\/klexin type 9\n                      <jats:bold>(<\/jats:bold>\n                      PCSK9) mass, oxidised low-density lipoprotein (oxLDL), small dense low-density lipoprotein cholesterol (sdLDL-C) and tumour necrosis factor \u03b1 (TNF-\u03b1).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with NPD-B, compared with age and sex matched reference group, had higher triglycerides, PCSK9, apoB48, oxLDL and TNF-\u03b1 and lower high density lipoprotein cholesterol (HDL-C) and apoA1. Treatment with ERT was associated with improved lipid parameters including total cholesterol, triglycerides, low density lipoprotein cholesterol (LDL-C), sdLDL-C, oxLDL and apoB100. Though there was an increase in apoA1, HDL-C was slightly reduced. TNF-\u03b1 showed a reduction. ApoB100 decreased in parallel with a decrease in total serum PCSK9 mass after ERT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that patients with NPD-B had a proatherogenic lipid profile and higher circulating TNF-\u03b1 compared to reference group. There was an improvement in dyslipidaemia after olipudase alfa. It was possible that reductions in LDL-C and apoB100 were driven by reductions in TNF-\u03b1 and PCSK9 following ERT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01739-y","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:03:36Z","timestamp":1614402216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changes in PCSK 9 and apolipoprotein B100 in Niemann\u2013Pick disease after enzyme replacement therapy with olipudase alfa"],"prefix":"10.1186","volume":"16","author":[{"given":"Bethanie","family":"Garside","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hoong","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaishav","family":"Dhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Donn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-5014","authenticated-orcid":false,"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"issue":"1\u20132","key":"1739_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann\u2013Pick disease. Mol Genet Metab. 2017;120(1\u20132):27\u201333.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"1739_CR2","first-page":"674","volume":"13","author":"EH Schuchman","year":"2016","unstructured":"Schuchman EH, Wasserstein MP. Types A and B Niemann\u2013Pick Disease. Pediatr Endocrinol Rev. 2016;13(Suppl 1):674\u201381.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"1739_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12(1):41.","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"1739_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ymgme.2015.05.013","volume":"116","author":"MP Wasserstein","year":"2015","unstructured":"Wasserstein MP, Jones SA, Soran H, Diaz GA, Lippa N, Thurberg BL, Culm-Merdek K, Shamiyeh E, Inguilizian H, Cox GF, Puga AC. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab. 2015;116(1\u20132):88\u201397.","journal-title":"Mol Genet Metab"},{"key":"1739_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","volume":"104","author":"XL Lin","year":"2018","unstructured":"Lin XL, Xiao LL, Tang ZH, Jiang ZS, Liu MH. Role of PCSK9 in lipid metabolism and atherosclerosis. Biomed Pharmacother. 2018;104:36\u201344.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1739_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"6","key":"1739_CR7","first-page":"659","volume":"45","author":"A Hafiane","year":"2015","unstructured":"Hafiane A, Genest J. HDL-mediated cellular cholesterol efflux assay method. Ann Clin Lab Sci. 2015;45(6):659\u201368.","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"1739_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","volume":"30","author":"M de la Llera-Moya","year":"2010","unstructured":"de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30(4):796\u2013801.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1739_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1373\/clinchem.2005.063412","volume":"52","author":"V Charlton-Menys","year":"2006","unstructured":"Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem. 2006;52(3):453\u20137.","journal-title":"Clin Chem"},{"key":"1739_CR10","unstructured":"Elabscience, Cat# E-EL-H6084, RRID:AB_2848155."},{"key":"1739_CR11","unstructured":"Elabscience, Cat# E-EL-H1642, RRID:AB_2848156."},{"key":"1739_CR12","unstructured":"R and D Systems, Cat# DY3888, RRID:AB_2848199."},{"key":"1739_CR13","unstructured":"Thermo Fisher Scientific, Cat# BMS223HS, RRID:AB_2575488."},{"issue":"1\u20132","key":"1739_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cca.2007.04.009","volume":"382","author":"V Charlton-Menys","year":"2007","unstructured":"Charlton-Menys V, Liu Y, Moorhouse A, Durrington PN. The robustness of the Roche 2nd generation homogenous HDL cholesterol (PEGME) method: assessment of the effect of serum sample storage for up to 8 years at \u2212\u200980 degrees C. Clin Chim Acta. 2007;382(1\u20132):142\u20134.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"1739_CR15","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.4049\/jimmunol.0902926","volume":"185","author":"S Jozefowski","year":"2010","unstructured":"Jozefowski S, Czerkies M, Lukasik A, Bielawska A, Bielawski J, Kwiatkowska K, Sobota A. Ceramide and ceramide 1-phosphate are negative regulators of TNF-alpha production induced by lipopolysaccharide. J Immunol. 2010;185(11):6960\u201373.","journal-title":"J Immunol"},{"key":"1739_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.plipres.2015.09.002","volume":"61","author":"A Gomez-Munoz","year":"2016","unstructured":"Gomez-Munoz A, Presa N, Gomez-Larrauri A, Rivera IG, Trueba M, Ordonez M. Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res. 2016;61:51\u201362.","journal-title":"Prog Lipid Res"},{"issue":"52","key":"1739_CR17","doi-asserted-by":"publisher","first-page":"44357","DOI":"10.1074\/jbc.M111.264010","volume":"286","author":"JL Hankins","year":"2011","unstructured":"Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M. Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression. J Biol Chem. 2011;286(52):44357\u201366.","journal-title":"J Biol Chem"},{"issue":"7","key":"1739_CR18","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","volume":"291","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J, Corsini A, Ferri N. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem. 2016;291(7):3508\u201319.","journal-title":"J Biol Chem"},{"issue":"1","key":"1739_CR19","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","volume":"8","author":"C Ricci","year":"2018","unstructured":"Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, Fogacci F, Corsini A, Ferri N. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8(1):2267.","journal-title":"Sci Rep"},{"key":"1739_CR20","unstructured":"Durrington PN. Hyperlipidaemia : diagnosis and management. 2nd ed. Oxford ; Boston: Butterworth-Heinemann."},{"key":"1739_CR21","doi-asserted-by":"publisher","first-page":"a993","DOI":"10.1136\/bmj.a993","volume":"337","author":"D Bhatnagar","year":"2008","unstructured":"Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ. 2008;337:a993.","journal-title":"BMJ"},{"issue":"1","key":"1739_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2018.72238","volume":"14","author":"H Soran","year":"2018","unstructured":"Soran H, Adam S, Mohammad JB, Ho JH, Schofield JD, Kwok S, Siahmansur T, Liu Y, Syed AA, Dhage SS, Stefanutti C, Donn R, Malik RA, Banach M, Durrington PN. Hypercholesterolaemia\u2014practical information for non-specialists. Arch Med Sci. 2018;14(1):1\u201321.","journal-title":"Arch Med Sci"},{"issue":"12","key":"1739_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1515\/CCLM.2004.254","volume":"42","author":"G Walldius","year":"2004","unstructured":"Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB\/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004;42(12):1355\u201363.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"1739_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","volume":"259","author":"PJ Barter","year":"2006","unstructured":"Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel. J Intern Med. 2006;259(3):247\u201358.","journal-title":"J Intern Med"},{"issue":"5","key":"1739_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11(5):367\u201383.","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"1739_CR26","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","volume":"132","author":"N Bergeron","year":"2015","unstructured":"Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648\u201366.","journal-title":"Circulation"},{"issue":"7","key":"1739_CR27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","volume":"32","author":"H Sun","year":"2012","unstructured":"Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol. 2012;32(7):1585\u201395.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1739_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12944-016-0339-8","volume":"15","author":"T Nozue","year":"2016","unstructured":"Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Hirano T, Michishita I. Correlation between serum levels of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis. 2016;15(1):165.","journal-title":"Lipids Health Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01739-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01739-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01739-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:10:09Z","timestamp":1614402609000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01739-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01739-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-60925\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-60925\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"16 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approvals for the study were obtained from Yorkshire & the Humber-Leeds East Research Ethics Committee and Health Research Authority. Informed consent was obtained from all reference group participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approvals and consent to participate"}},{"value":"Participants were made aware that anonymised results would be published in peer-reviewed journals. As all study data were anonymised, journal publication was approved by Ethics without need for further participant consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}